Under terms of the deal, Alchemab will lead early Phase I trials for ATLX-1282 in amyotrophic lateral sclerosis, while Lilly ...

The Refusal to File letter comes despite the FDA’s prior encouragement to submit a supplemental biologics license application ...

Blake Powers, CEO, medigi, explains how digital tools, AI, and automation are streamlining access to biosimilars and cell and gene therapies, signaling a shift toward more tech-enabled, ...

Fran Gregory, VP, emerging therapies, Cardinal Health, emphasizes the need for long-term outcomes tracking and robust health economic modeling to demonstrate the sustained value of advanced therapies ...

PE: What alternate strategies would have a better impact on reducing drug costs? Mendelsohn: Pushing for lower out-of-pocket ...

Chip Parkinson, CEO, GiftHealth, explains how AI-powered data integration is bringing new hope to patients by revealing ...

Kapil Raina, MD, Principal of Market Access at Herspiegel Consulting, talks about disconnects in the industry, how patients have easier access to healthcare information, and the exciting future of ...

Selarsdi, a biosimilar to Stelara, is approved for adult and pediatric psoriatic arthritis, plaque psoriasis, Crohn disease, ...

Medicare drug price negotiations will reshape market access, provider reimbursement, and patient care ...

The 470,000-square-foot facility will support the launch and commercial production of next-generation biologics and therapies ...

Sanofi announced an expansion of its partnership with McLaren Racing. The two companies, alongside United Autosports, are ...

Tiara Green, president, Accessia Health, explains how empowering trusted local leaders and involving communities early are ...